Citi launched broad coverage of major European pharmaceutical companies with a mixed outlook, issuing Buy ratings on AstraZeneca and Novartis while taking a more cautious stance on GSK, Novo Nordisk ...
Liminatus Pharma, Inc. is a pre-clinical-stage immuno-oncology company, which engages in developing novel, immune-modulating cancer therapies. The company was founded on November 1, 2020 and is ...
Fierce Pharma Asia—Astellas' first-in-class FDA nod; Otsuka's IgAN win; Samsung Bio's $1.2B contract
Astellas' first-in-class CLDN18.2 drug Vyloy has cleared the FDA. After a positive phase 3 readout, Otsuka is targeting an accelerated approval filing for a kidney disease candidate. Samsung Biologics ...
Royalty Pharma announces $0.22 dividend per share for Q2 2025, payable on June 10 to shareholders of record by May 16. Royalty Pharma plc has announced that its board of directors has approved a ...
SOUTH SAN FRANCISCO, Calif.--(BUSINESS WIRE)--Circle Pharma, a clinical-stage biopharmaceutical company dedicated to discovering and developing a new generation of macrocycle therapies, today ...
EPIX investors may also contact Joseph E. Levi, Esq. via email at [email protected] or by telephone at (212) 363-7500. CASE DETAILS: The filed complaint alleges that defendants made false ...
NEW YORK, NY / ACCESS Newswire / March 3, 2025 / If you suffered a loss on your ESSA Pharma Inc. (NASDAQ:EPIX) investment and want to learn about a potential recovery under the federal securities laws ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results